Piramal Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., has announced a significant expansion of its manufacturing capabilities in partnership with NewAmsterdam Pharma Company N.V. The companies have unveiled a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA.

Multi-Million Dollar Investment

The new suite represents a multi-million-dollar investment aimed at enhancing Piramal's oral solid dosage production capabilities. This strategic move is designed to meet the potentially high commercial demand for NewAmsterdam Pharma's fixed dose combination (FDC) of obicetrapib and ezetimibe, a non-statin cholesterol medication to reduce LDL-C.

Enhanced Manufacturing Capabilities

The dedicated OSD suite is equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. It has been specifically designed for turnkey, multi-layer tablet production, which will significantly improve operational efficiency in delivering NewAmsterdam Pharma's investigational drug therapy, pending approval.

Job Creation and Economic Impact

This expansion is not only beneficial for the companies involved but also for the local economy. Over the next five years, the new suite is expected to create more than 20 new jobs at the Sellersville site, contributing to the local workforce and economic growth.

Integrated Approach to Development

Piramal Pharma Solutions has demonstrated the advantages of its integrated approach to development by leveraging the strengths of multiple facilities:

• The Sellersville site will house the new dedicated OSD suite
• The Ahmedabad PPDS, India site played a crucial role in the product's development
• The Pithampur, India site provides dual sourcing support

This collaborative effort across facilities showcases Piramal's comprehensive capabilities in drug development and manufacturing.

Executive Insights

Peter DeYoung, CEO of Piramal Global Pharma, expressed enthusiasm about the expansion, stating, "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too."

Douglas Kling, COO of NewAmsterdam Pharma, highlighted the strategic importance of the investment, saying, "We are enabling the manufacture of the FDC with exceptional precision and efficiency to meet the future commercial demand."

Looking Ahead

The partnership between Piramal Pharma Solutions and NewAmsterdam Pharma represents a significant step forward in pharmaceutical manufacturing. By investing in advanced production capabilities, both companies are positioning themselves to meet growing market demands and potentially benefit countless patients globally with innovative cholesterol-lowering therapies.

As the pharmaceutical industry continues to evolve, collaborations like this one between Piramal Pharma and NewAmsterdam Pharma demonstrate the importance of strategic partnerships in bringing new medications to market efficiently and at scale.

Piramal Pharma Limited (PPL) has announced a significant investment through its subsidiary, marking a major move in the pharmaceutical sector. The company's material step-down wholly owned subsidiary, Piramal Healthcare Inc., has completed a substantial capital deployment of $190.30 million (approximately ₹1,626.49 crore) in PPL Pharma Inc., another step-down wholly owned subsidiary of Piramal Pharma Limited.

Investment Details

The investment, completed on August 20, 2025, involves the subscription of 1,903 optionally convertible redeemable preference shares of PPL Pharma Inc., each with a face value of $100,000. This strategic move represents a considerable financial commitment by the Piramal Pharma group towards its subsidiary operations.

Regulatory Compliance

In adherence to regulatory requirements, Piramal Pharma Limited disclosed this information under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The company had previously intimated this development on April 23, 2025, showcasing its commitment to transparent communication with stakeholders.

Corporate Structure

Both Piramal Healthcare Inc. and PPL Pharma Inc. are step-down wholly owned subsidiaries of Piramal Pharma Limited. This investment structure highlights the company's strategy of strengthening its pharmaceutical business through internal capital allocation.

Upcoming Investor Engagements

Piramal Pharma has also announced a series of upcoming analyst and institutional investor meetings:

• September 16-17, 2025: Participation in Goldman Sachs Global CDMO Day in Singapore
• September 18, 2025: Investor meetings in Singapore
• September 19, 2025: Participation in Kotak Healthcare Forum 2025 in Mumbai

These engagements underscore Piramal Pharma's active approach to investor relations and its commitment to maintaining open lines of communication with the financial community.

The substantial investment in PPL Pharma Inc. and the scheduled investor meetings indicate Piramal Pharma's focus on growth and stakeholder engagement in the pharmaceutical sector.